Do analysts recommend INGN or CBLL?

CeriBell has a consensus target price of $21.80, indicating a potential upside of 12.95%. Given CeriBell's stronger consensus rating and higher possible upside, analysts clearly believe CeriBell is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 CeriBell 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83

Which has preferable valuation and earnings, INGN or CBLL?

Inogen has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inogen $348.67M 0.47 -$22.75M -$0.90 N/A CeriBell $95.07M 7.70 -$53.41M -$1.63 N/A

Is INGN or CBLL more profitable?

Inogen has a net margin of -6.94% compared to CeriBell's net margin of -63.51%. Inogen's return on equity of -13.17% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets Inogen -6.94% -13.17% -8.36% CeriBell -63.51% -38.19% -30.92%

Does the media refer more to INGN or CBLL?

In the previous week, CeriBell had 2 more articles in the media than Inogen. MarketBeat recorded 11 mentions for CeriBell and 9 mentions for Inogen. CeriBell's average media sentiment score of 0.29 beat Inogen's score of 0.28 indicating that CeriBell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inogen 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral CeriBell 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts prefer TCMD or INGN?

Tactile Systems Technology currently has a consensus price target of $38.40, indicating a potential upside of 31.78%. Given Tactile Systems Technology's stronger consensus rating and higher probable upside, analysts clearly believe Tactile Systems Technology is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tactile Systems Technology 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Does the media refer more to TCMD or INGN?

In the previous week, Tactile Systems Technology had 1 more articles in the media than Inogen. MarketBeat recorded 10 mentions for Tactile Systems Technology and 9 mentions for Inogen. Tactile Systems Technology's average media sentiment score of 1.31 beat Inogen's score of 0.28 indicating that Tactile Systems Technology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tactile Systems Technology 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inogen 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer INGN or ANGO?

AngioDynamics has a consensus price target of $19.50, suggesting a potential upside of 23.81%. Given AngioDynamics' higher probable upside, analysts plainly believe AngioDynamics is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 AngioDynamics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.40

Which has preferable earnings & valuation, INGN or ANGO?

Inogen has higher revenue and earnings than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inogen $348.67M 0.47 -$22.75M -$0.90 N/A AngioDynamics $320.17M 2.03 -$36.74M -$0.87 N/A

Is INGN or ANGO more profitable?

Inogen has a net margin of -6.94% compared to AngioDynamics' net margin of -11.48%. AngioDynamics' return on equity of -5.73% beat Inogen's return on equity. Company Net Margins Return on Equity Return on Assets Inogen -6.94% -13.17% -8.36% AngioDynamics -11.48% -5.73% -3.77%

Does the media prefer INGN or ANGO?

In the previous week, AngioDynamics had 7 more articles in the media than Inogen. MarketBeat recorded 16 mentions for AngioDynamics and 9 mentions for Inogen. Inogen's average media sentiment score of 0.28 beat AngioDynamics' score of -0.13 indicating that Inogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inogen 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral AngioDynamics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer BWAY or INGN?

Brainsway currently has a consensus target price of $15.67, suggesting a potential upside of 2.26%. Given Brainsway's stronger consensus rating and higher probable upside, analysts plainly believe Brainsway is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainsway 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has stronger earnings & valuation, BWAY or INGN?

Brainsway has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainsway $52.22M 11.77 $7.57M $0.35 43.77 Inogen $348.67M 0.47 -$22.75M -$0.90 N/A

Is BWAY or INGN more profitable?

Brainsway has a net margin of 15.68% compared to Inogen's net margin of -6.94%. Brainsway's return on equity of 12.28% beat Inogen's return on equity. Company Net Margins Return on Equity Return on Assets Brainsway 15.68% 12.28% 7.75% Inogen -6.94% -13.17% -8.36%

Does the media favor BWAY or INGN?

In the previous week, Inogen had 4 more articles in the media than Brainsway. MarketBeat recorded 9 mentions for Inogen and 5 mentions for Brainsway. Brainsway's average media sentiment score of 0.85 beat Inogen's score of 0.28 indicating that Brainsway is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Brainsway 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inogen 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BBNX or INGN?

Beta Bionics currently has a consensus price target of $20.10, suggesting a potential upside of 22.56%. Given Beta Bionics' stronger consensus rating and higher possible upside, research analysts clearly believe Beta Bionics is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beta Bionics 1 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.55 Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has preferable valuation & earnings, BBNX or INGN?

Inogen has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Beta Bionics $100.25M 7.36 -$73.20M -$1.65 N/A Inogen $348.67M 0.47 -$22.75M -$0.90 N/A

Is BBNX or INGN more profitable?

Inogen has a net margin of -6.94% compared to Beta Bionics' net margin of -61.31%. Inogen's return on equity of -13.17% beat Beta Bionics' return on equity. Company Net Margins Return on Equity Return on Assets Beta Bionics -61.31% -26.30% -23.25% Inogen -6.94% -13.17% -8.36%

Does the media prefer BBNX or INGN?

In the previous week, Inogen had 6 more articles in the media than Beta Bionics. MarketBeat recorded 9 mentions for Inogen and 3 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 0.99 beat Inogen's score of 0.28 indicating that Beta Bionics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inogen 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Inogen (INGN) Competitors

$6.02 -0.03 (-0.50%)

Closing price 08/10/2026 04:00 PM Eastern

Extended Trading

$6.14 +0.12 (+1.91%)

As of 08:40 AM Eastern

Compare

INGN vs. CBLL, TCMD, ANGO, BWAY, and BBNX

Should you buy Inogen stock or one of its competitors? Inogen's main competitors and comparable companies include CeriBell (CBLL), Tactile Systems Technology (TCMD), AngioDynamics (ANGO), Brainsway (BWAY), and Beta Bionics (BBNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Inogen compare to CeriBell?

Inogen (NASDAQ:INGN) and CeriBell (NASDAQ:CBLL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

In the previous week, CeriBell had 2 more articles in the media than Inogen. MarketBeat recorded 11 mentions for CeriBell and 9 mentions for Inogen. CeriBell's average media sentiment score of 0.29 beat Inogen's score of 0.28 indicating that CeriBell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inogen	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
CeriBell	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Inogen has a net margin of -6.94% compared to CeriBell's net margin of -63.51%. Inogen's return on equity of -13.17% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inogen	-6.94%	-13.17%	-8.36%
CeriBell	-63.51%	-38.19%	-30.92%

Inogen has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, CeriBell has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

Inogen has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$348.67M	0.47	-$22.75M	-$0.90	N/A
CeriBell	$95.07M	7.70	-$53.41M	-$1.63	N/A

89.9% of Inogen shares are owned by institutional investors. 2.5% of Inogen shares are owned by insiders. Comparatively, 17.7% of CeriBell shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CeriBell has a consensus target price of $21.80, indicating a potential upside of 12.95%. Given CeriBell's stronger consensus rating and higher possible upside, analysts clearly believe CeriBell is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Inogen beats CeriBell on 9 of the 16 factors compared between the two stocks.

How does Inogen compare to Tactile Systems Technology?

Tactile Systems Technology (NASDAQ:TCMD) and Inogen (NASDAQ:INGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

In the previous week, Tactile Systems Technology had 1 more articles in the media than Inogen. MarketBeat recorded 10 mentions for Tactile Systems Technology and 9 mentions for Inogen. Tactile Systems Technology's average media sentiment score of 1.31 beat Inogen's score of 0.28 indicating that Tactile Systems Technology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tactile Systems Technology	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inogen	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tactile Systems Technology has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tactile Systems Technology	$329.52M	2.00	$19.09M	$0.88	33.11
Inogen	$348.67M	0.47	-$22.75M	-$0.90	N/A

Tactile Systems Technology currently has a consensus price target of $38.40, indicating a potential upside of 31.78%. Given Tactile Systems Technology's stronger consensus rating and higher probable upside, analysts clearly believe Tactile Systems Technology is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tactile Systems Technology	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Tactile Systems Technology has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Inogen has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market.

83.4% of Tactile Systems Technology shares are held by institutional investors. Comparatively, 89.9% of Inogen shares are held by institutional investors. 2.1% of Tactile Systems Technology shares are held by company insiders. Comparatively, 2.5% of Inogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Tactile Systems Technology has a net margin of 5.91% compared to Inogen's net margin of -6.94%. Tactile Systems Technology's return on equity of 9.70% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tactile Systems Technology	5.91%	9.70%	7.53%
Inogen	-6.94%	-13.17%	-8.36%

Summary

Tactile Systems Technology beats Inogen on 12 of the 17 factors compared between the two stocks.

How does Inogen compare to AngioDynamics?

Inogen (NASDAQ:INGN) and AngioDynamics (NASDAQ:ANGO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

AngioDynamics has a consensus price target of $19.50, suggesting a potential upside of 23.81%. Given AngioDynamics' higher probable upside, analysts plainly believe AngioDynamics is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
AngioDynamics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40

Inogen has a net margin of -6.94% compared to AngioDynamics' net margin of -11.48%. AngioDynamics' return on equity of -5.73% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inogen	-6.94%	-13.17%	-8.36%
AngioDynamics	-11.48%	-5.73%	-3.77%

Inogen has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market. Comparatively, AngioDynamics has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market.

In the previous week, AngioDynamics had 7 more articles in the media than Inogen. MarketBeat recorded 16 mentions for AngioDynamics and 9 mentions for Inogen. Inogen's average media sentiment score of 0.28 beat AngioDynamics' score of -0.13 indicating that Inogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inogen	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
AngioDynamics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

89.9% of Inogen shares are owned by institutional investors. Comparatively, 89.4% of AngioDynamics shares are owned by institutional investors. 2.5% of Inogen shares are owned by insiders. Comparatively, 6.0% of AngioDynamics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Inogen has higher revenue and earnings than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$348.67M	0.47	-$22.75M	-$0.90	N/A
AngioDynamics	$320.17M	2.03	-$36.74M	-$0.87	N/A

Summary

Inogen and AngioDynamics tied by winning 8 of the 16 factors compared between the two stocks.

How does Inogen compare to Brainsway?

Brainsway (NASDAQ:BWAY) and Inogen (NASDAQ:INGN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Brainsway currently has a consensus target price of $15.67, suggesting a potential upside of 2.26%. Given Brainsway's stronger consensus rating and higher probable upside, analysts plainly believe Brainsway is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

30.1% of Brainsway shares are held by institutional investors. Comparatively, 89.9% of Inogen shares are held by institutional investors. 19.0% of Brainsway shares are held by insiders. Comparatively, 2.5% of Inogen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Inogen had 4 more articles in the media than Brainsway. MarketBeat recorded 9 mentions for Inogen and 5 mentions for Brainsway. Brainsway's average media sentiment score of 0.85 beat Inogen's score of 0.28 indicating that Brainsway is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainsway	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inogen	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Brainsway has a net margin of 15.68% compared to Inogen's net margin of -6.94%. Brainsway's return on equity of 12.28% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainsway	15.68%	12.28%	7.75%
Inogen	-6.94%	-13.17%	-8.36%

Brainsway has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, Inogen has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market.

Brainsway has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$52.22M	11.77	$7.57M	$0.35	43.77
Inogen	$348.67M	0.47	-$22.75M	-$0.90	N/A

Summary

Brainsway beats Inogen on 12 of the 16 factors compared between the two stocks.

How does Inogen compare to Beta Bionics?

Beta Bionics (NASDAQ:BBNX) and Inogen (NASDAQ:INGN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

89.9% of Inogen shares are held by institutional investors. 5.3% of Beta Bionics shares are held by insiders. Comparatively, 2.5% of Inogen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Inogen had 6 more articles in the media than Beta Bionics. MarketBeat recorded 9 mentions for Inogen and 3 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 0.99 beat Inogen's score of 0.28 indicating that Beta Bionics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inogen	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inogen has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	7.36	-$73.20M	-$1.65	N/A
Inogen	$348.67M	0.47	-$22.75M	-$0.90	N/A

Beta Bionics has a beta of 3.13, suggesting that its stock price is 213% more volatile than the broader market. Comparatively, Inogen has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market.

Beta Bionics currently has a consensus price target of $20.10, suggesting a potential upside of 22.56%. Given Beta Bionics' stronger consensus rating and higher possible upside, research analysts clearly believe Beta Bionics is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Inogen has a net margin of -6.94% compared to Beta Bionics' net margin of -61.31%. Inogen's return on equity of -13.17% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-61.31%	-26.30%	-23.25%
Inogen	-6.94%	-13.17%	-8.36%

Summary

Inogen beats Beta Bionics on 10 of the 17 factors compared between the two stocks.

Get Inogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INGN vs. The Competition

Export

Metric	Inogen	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$163.80M	$5.84B	$7.02B	$12.98B
Dividend Yield	N/A	1.78%	2.58%	10.06%
P/E Ratio	-6.69	24.72	269.18	24.72
Price / Sales	0.47	39.71	585.29	95.49
Price / Cash	N/A	33.55	28.89	37.42
Price / Book	0.85	6.21	11.26	6.42
Net Income	-$22.75M	$147.87M	$3.45B	$347.03M
7 Day Performance	-13.01%	1.08%	1.91%	0.71%
1 Month Performance	-7.95%	1.65%	-0.58%	-0.87%
1 Year Performance	-14.49%	5.39%	75.47%	21.94%

Inogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INGN Inogen	1.2645 of 5 stars	$6.02 -0.5%	N/A	-7.1%	$163.80M	$348.67M	N/A	1,030	Earnings Report
CBLL CeriBell	2.0496 of 5 stars	$18.31 +3.5%	$22.20 +21.2%	+49.5%	$671.21M	$89.06M	N/A	N/A	Trending News Earnings Report
TCMD Tactile Systems Technology	4.0075 of 5 stars	$29.78 +5.7%	$38.60 +29.6%	+137.3%	$635.41M	$329.52M	33.84	1,086	News Coverage Positive News Earnings Report Analyst Forecast
ANGO AngioDynamics	3.3256 of 5 stars	$15.17 +2.6%	$19.50 +28.5%	+85.1%	$611.31M	$320.17M	N/A	760
BWAY Brainsway	4.0277 of 5 stars	$15.81 +3.8%	$15.67 -0.9%	+160.5%	$611.20M	$52.22M	45.17	120	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INGN) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inogen (INGN) Competitors